HS: Positive Results Reported With Anti-IL17A/F Therapies

One of the trials evaluated a nanobody inhibitor, sonelokimab, a molecule with a substantially smaller size than traditional monoclonal antibodies.

Related Keywords

Germany ,Berlin ,United States ,Neuruppin ,Brandenburg , ,Brandenburg Medical School ,European Union ,Drug Administration ,Hidradenitis Suppurativa ,Skin And Soft Tissue Infection ,Biologic Therapy ,Iologics ,Monoclonal Antibody ,Etuximab ,Ituximab ,Abscess ,Europe ,European ,Dentistry ,Oral Health ,Oral Medicine ,Mental Health ,Ental ,Rural Healthcare ,Rural Health Care ,Psoriatic Arthritis ,Rthropathic Psoriasis ,Psoriatic Arthropathy ,Sa ,Psoriasis ,Nodule ,Ankylosing Spondylitis ,Heumatoid Spondylitis ,